Mitigating FCPA Risks in Pharma, Med Device Sectors
Image: SEC Enforcement Director Andrew Ceresney recently dropped new hints on FCPA risks for pharma and medical devices, plus suggestions on how to avoid those risks. “Our FCPA focus obviously covers many industries,” he said. “But the pharma industry is one on which we have been particularly focused in recent ...
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
OpinionMisused and abused: What the President’s pardon power would do to your compliance team
President Donald Trump’s unprecedented misuse and abuse of a pardon power that dates back 250 years serves as a real-world scenario of what can happen when a system of checks-and-balances – like, say, a corporate ethics and compliance program – is upended by a tyrannical executive.
-
SurveyHow Ethics & Compliance Teams Are Adopting Artificial Intelligence (AI) Tools
This survey will explore how ethics & compliance (E&C) officers are adopting and leveraging artificial intelligence (AI), particularly generative AI, within their programs.
-
OpinionWrite supply chain resilience into the contract
The only thing constant is change. Shouldn’t we be ready for that in our contracts?